Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis (Q45184240)

10 December 2017

0 references

Anti-TNF-α therapy for patients with sepsis: a systematic meta-analysis (English)

1 reference

10 December 2017

0 references

0 references

1 reference

1 reference

S Lv

1

1 reference

10 December 2017

M Han

2

1 reference

10 December 2017

R Yi

3

1 reference

10 December 2017

S Kwon

4

1 reference

10 December 2017

C Dai

5

1 reference

10 December 2017

R Wang

6

1 reference

10 December 2017

18 February 2014

1 reference

International Journal of Clinical Practice

10 December 2017

1 reference

10 December 2017

68

1 reference

10 December 2017

4

1 reference

10 December 2017

520-528

1 reference

Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy

10 December 2017

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Treatment options for severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

The role of tumor necrosis factor in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis--a randomized, clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

A placebo-controlled, double-blind, dose-escalation study to assess the safety, tolerability and pharmacokinetics/pharmacodynamics of single and multiple intravenous infusions of AZD9773 in patients with severe sepsis and septic shock.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

A Phase II study of polyclonal anti-TNF-α (AZD9773) in Japanese patients with severe sepsis and/or septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

The potential for HIV fusion inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Anti-inflammatory therapies in sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Tumor necrosis factor-dependent adhesions as a major protective mechanism early in septic peritonitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

Neutralization of tumor necrosis factor in preclinical models of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FIJCP.12382

21 January 2018

Identifiers

DOI

10.1111/IJCP.12382

1 reference

release_wq36vcbsfvdjnb3usl5o4hzufi

10 December 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wq36vcbsfvdjnb3usl5o4hzufi

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference